12:20 PM EDT, 08/12/2025 (MT Newswires) -- Insmed ( INSM ) said Tuesday the US Food and Drug Administration has approved Brinsupri to treat non-cystic fibrosis bronchiectasis in adults and children 12 years and above.

Brinsupri is the first and only FDA-approved treatment for NCFB, the company said.

Shares of Insmed ( INSM ) were up over 4% in recent trading.

Price: 117.91, Change: +5.02, Percent Change: +4.44